CDMO Services for Europe
EU GMP-Compliant Contract Development & Manufacturing from India
Shilpa Pharma is a world-class CDMO in India delivering high-quality, compliant, and scalable contract development and manufacturing services to pharmaceutical, biotech, and specialty chemical companies across Europe. As a globally trusted Contract Development and Manufacturing Organization, Our manufacturing facilities in India are designed and operated in full compliance with EU GMP guidelines, and we actively support European partners with EMA submissions, ASMF filings, and CEP applications.
With decades of experience serving regulated markets and a proven track record with leading global pharma innovators, our CDMO in India combines advanced development expertise, cGMP-compliant manufacturing infrastructure, and deep regulatory capabilities to support European pharmaceutical companies of every scale. From multinational corporations to early-stage biotech startups, we are equipped to handle your full development and manufacturing lifecycle. Our India-based CDMO services enable European companies to accelerate product development, ensure regulatory readiness, significantly reduce manufacturing costs, and build resilient EU-compliant global supply chains.
Our CDMO Specialties
- High pressure reaction with Pd/Ru/Rd etc., Hydrogenation
- Brominating/Chlorination
- Cyanation
- Electro-chemical reactions
- Asymmetric synthesis
- Cryogenic reactions (up to -90°C)
- Boron Chemistry
- Hydrogenation including asymmetric capabilities
- Butyl Lithium Reaction
- Chiral Synthesis
- Cyclopropane Chemistry
- Grignard Reaction
- Indole Chemistry
- Nucleoside Chemistry
- Purine Chemistry
- Pyridine Chemistry
- Pyrimidine Chemistry
- Steroid Chemistry
- Oxidation and reduction reactions
- Pressure reactions
- Enzymatic reactions
- Use of phase transfer catalyst
- Cytotoxic (Onco) products Can handle with isolators.
Contact for End-to-End CDMO Services in Europe
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Regulatory Certifications & Market Access
Shilpa Pharma’s manufacturing facilities are audited and certified by the world’s most stringent regulatory authorities, making us immediately credible and documentation-ready for European market submissions with zero ramp-up time.
Why European Companies Choose Shilpa Pharma as Their CDMO Partner
As a globally accredited CDMO in India, Shilpa Pharma delivers end-to-end, compliant, and cost-effective solutions backed by expertise in complex chemistries, advanced formulations, and the full spectrum of European regulatory requirements. Our proven quality systems, fast EU GMP documentation turnaround, and trusted partnerships across regulated markets make us the preferred choice for European pharma innovators at every stage.
End-to-End CDMO Solutions
From route scouting and process development to GMP manufacturing and commercial supply — we cover every stage of the drug development lifecycle under one roof.
State-of-the-Art R&D
Advanced laboratories for formulation, biologics, and peptide research.
Global Quality Standards
GMP-compliant facilities ensuring regulatory-ready production.
Advanced Manufacturing Capabilities
High-potent APIs, continuous flow chemistry, and scalable processes.
Sustainable & Compliant Operations
Environmentally responsible practices with stringent safety protocols.
Trusted by Pharma Innovators
Reliable partnerships delivering complex projects on time and within budget.
Contract Manufacturing for European Pharmaceutical Companies
As a trusted Contract Manufacturing Organization, Shilpa Pharma delivers precision-driven, compliant, and scalable commercial manufacturing from India for European pharmaceutical companies. Our state-of-the-art manufacturing facilities in India support everything from small-batch development manufacturing to large-scale commercial production, ensuring consistent quality, EU GMP adherence, and dependable global supply.
We specialize in the manufacturing of complex APIs, high-potency compounds, specialty therapeutics, oncology molecules, and advanced pharmaceutical products. Every program is executed under strict EU GMP, US FDA, cGMP, CDSCO, and global regulatory protocols. Every manufacturing engagement is managed with full transparency, robust documentation, and stringent quality controls that meet and exceed the expectations of the European pharmaceutical and biotech market.
Manufacturing Strengths
- Precision and Compliance Manufacturing systems fully aligned with EU GMP, EMA, EDQM, ICH, and cGMP guidelines, with complete audit trails and data integrity controls at every stage.
- Advanced Infrastructure Facilities in India engineered for complex, high-potency, and high-value pharmaceutical products, including dedicated cytotoxic suites with isolator technology for oncology compounds.
- End-to-End Production Seamless execution from technology transfer and process scale-up to long-term commercial supply, with full change management and continuous regulatory support throughout the program lifecycle.
- Multi-Market Regulatory Coverage Simultaneous compliance with EU GMP, US FDA, TGA, PMDA, KFDA, ANVISA, and COFEPRIS, enabling pan-global supply from a single India-based manufacturing source for European companies targeting multiple international markets.
Contract Development for Europe
Shilpa Pharma’s Contract Development services support European pharmaceutical and biotech companies with regulatory-ready, scalable, and scientifically robust drug development solutions. Backed by strong R&D capabilities and advanced development infrastructure in India, we support programs across every stage — from route scouting and process optimization to formulation development, analytical method validation, and pilot-scale manufacturing.
Our development teams collaborate closely with European partners to design efficient, scalable, and EU GMP-compliant development pathways — fully aligned with EMA, ICH Q8/Q9/Q10/Q11/Q12 guidelines, and EU CTD format requirements. This approach ensures smooth technology transfer, strong data integrity, and development packages that directly support ASMF/DMF filings, CEP applications, and successful EMA regulatory submissions.
Questions & Answers
Our FAQ's
What CDMO services does Shilpa Pharma provide for European pharmaceutical companies?
Shilpa Pharma offers comprehensive end-to-end CDMO services from India, including contract development, API and formulation manufacturing, analytical method development and validation, process scale-up, stability studies, regulatory dossier preparation, and commercial production. All services are fully aligned with EU GMP, EMA, EDQM, and ICH regulatory standards for the European market.
Why should European pharma companies outsource to a CDMO in India?
Outsourcing to a CDMO in India like Shilpa Pharma offers European companies a powerful combination of cost efficiency, regulatory compliance, and scientific depth. India-based CDMO services deliver 30 to 50 percent cost savings over EU-based manufacturing alternatives, while our EU GMP certification, multi-market regulatory approvals, and 100-plus PhD-level R&D team ensure no compromise on quality or compliance. For European companies looking to accelerate development timelines and strengthen their supply chains, partnering with a CDMO in India is a strategic advantage.
How does a CDMO in India compare to a European CMO for quality and compliance?
Shilpa Pharma’s CDMO facilities in India are EU GMP certified and audited by European competent authorities, placing us at the same compliance level as EU-based CMOs. Additionally, our multi-regulatory approval status covering US FDA, TGA, PMDA, KFDA, ANVISA, and COFEPRIS means European companies gain access to a manufacturing partner with broader global market coverage than most European CMOs, at a significantly lower cost base.
Are Shilpa Pharma's facilities EU GMP certified?
Yes. Our manufacturing facilities in India are EU GMP certified and have successfully completed multiple audits by European competent authorities. We maintain active EU GMP certificates and are fully equipped to support CEP applications, ASMF filings, and EU CTD submissions for the European pharmaceutical market.
Does Shilpa Pharma work with European pharma startups?
Absolutely. We have dedicated engagement models for early-stage European biotech and pharma startups, offering flexible batch sizes, milestone-based contracts, hands-on regulatory guidance, and a seamless scale-up pathway from development to commercial manufacturing. Startups benefit from working with a single CDMO in India partner across the entire product lifecycle, reducing handover risk and protecting institutional knowledge.
Can Shilpa Pharma manufacture high-potency APIs and oncology compounds for the European market?
Yes. We have dedicated high-potency API manufacturing suites and cytotoxic compound handling capabilities with isolators at our India CDMO facility, fully compliant with EU GMP requirements for oncology and HPAPI products.
Does Shilpa Pharma support European regulatory submissions including ASMF, CEP, and EMA dossiers?
Yes. Our regulatory affairs team has extensive experience preparing EU CTD-format dossiers, Active Substance Master Files, Certificate of Suitability applications, and supporting EMA marketing authorization submissions for European partners across multiple therapeutic areas.
What cost advantage does outsourcing CDMO services to India offer European companies?
India-based CDMO services typically deliver 30 to 50 percent cost savings compared to European in-house manufacturing or EU-based CMO partnerships, without any compromise on quality, compliance, or documentation standards. These savings can be reinvested into R&D pipelines, clinical programs, or European market expansion activities.
How does Shilpa Pharma ensure supply reliability for European partners?
We ensure supply reliability through robust quality management systems, validated manufacturing processes, transparent operations, redundant sourcing strategies, and dependable production scheduling, ensuring consistent and on-time delivery to European customers across all program stages.
Does Shilpa Pharma comply with EU sustainability and ESG requirements?
Yes. Our CDMO operations in India include environmentally responsible manufacturing practices, solvent recovery systems, green chemistry protocols, and full ESG and SDG-aligned supply chain documentation, meeting the requirements of European corporations with sustainability mandates and CSRD reporting obligations.
Countries We Serve in
Learn About CMO Contract Manufacturing development in India to European Market
Leading CDMO in India Serving the European Pharmaceutical Market
Shilpa Pharma is a globally trusted, India-based Contract Development and Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies across Europe. Recognized for our EU GMP-compliant manufacturing, deep regulatory expertise, and advanced scientific capabilities, we help European innovators accelerate drug development, reduce manufacturing costs, and deliver high-quality medicines to regulated markets across the EU, UK, and beyond.
What Is a CDMO?
A CDMO (Contract Development and Manufacturing Organization) is a strategic outsourcing partner that supports pharmaceutical and biotech companies across both drug development and manufacturing stages. CDMOs offer integrated services including API process development, formulation development, analytical method development and validation, clinical supply manufacturing, scale-up, and commercial-scale production — all under one roof.
By partnering with a CDMO, European pharmaceutical companies can focus on research, pipeline innovation, and market expansion while relying on an experienced organization to manage compliant, efficient, and scalable development and manufacturing operations. CDMOs play a critical role in accelerating timelines, reducing per-unit costs, managing regulatory complexity, and delivering EU GMP-compliant, regulation-ready medicines for the European market.
Why Choose Shilpa Pharma as Your CDMO Partner for the European Market?
Shilpa Pharma combines scientific depth, regulatory strength, and proven manufacturing performance — making us a trusted CDMO in India for European pharmaceutical and biotech companies. Our manufacturing facilities in India are EU GMP certified and operate under stringent global quality standards, with approvals from all major international regulatory authorities including EU GMP, US FDA, PMDA, TGA, COFEPRIS, KFDA, and ANVISA.
What We Offer for European Partners:
- End-to-end CDMO support from early development through commercial manufacturing, aligned with EU GMP and EMA guidelines
- Expertise in complex APIs, oncology therapies, high-potency compounds, and specialty molecules
- Full regulatory support including ASMF filings, CEP applications, and EU CTD-format dossier preparation
- Robust quality systems with strict confidentiality, data integrity controls, and reliable supply performance for European markets
- Dedicated CDMO engagement models for European biotech startups — flexible batch sizes, milestone-based contracts, and a seamless scale-up pathway
- Flexible and scalable CDMO solutions with 30 to 50 percent cost advantage over EU-based manufacturing alternatives
Whether you require specialized contract development services, clinical supply manufacturing, or large-scale commercial API production for Europe, Shilpa Pharma delivers precision, compliance, and consistent quality for the most demanding regulated markets.
CDMO in India for Europe: Key Service Areas
As a full-service CDMO in India for European pharmaceutical companies, Shilpa Pharma supports programs across all major service areas required by the European market. Our contract development services cover route scouting, process optimization, analytical validation, formulation development, stability studies, and pilot-scale GMP manufacturing. Our contract manufacturing services support everything from small-batch clinical supply to large-scale commercial API and formulation production, with complete EU GMP documentation and regulatory readiness at every stage.
We specialize in complex chemistry including asymmetric synthesis, cryogenic reactions, high-pressure hydrogenation, chiral synthesis, HPAPI manufacturing, and cytotoxic compound production with dedicated isolators — capabilities that are directly relevant to the advanced molecule pipelines of European pharmaceutical innovators.
EU GMP Certified CDMO: Regulatory Readiness for Europe
For European pharmaceutical companies, regulatory compliance is non-negotiable. Shilpa Pharma’s India-based CDMO facilities hold active EU GMP certification and have successfully completed multiple audits by European competent authorities. This means your program begins with a regulatory-ready manufacturing base — no compliance ramp-up, no documentation gaps, no delays at the European border.
Our regulatory affairs team has extensive experience supporting European partners with Active Substance Master File (ASMF) preparation, Certificate of Suitability (CEP) applications through EDQM, EU CTD-format dossier compilation, and ongoing EMA submission support. We ensure your development data and manufacturing documentation are structured for seamless European regulatory review from day one.
CDMO for European Biotech Startups and Emerging Pharma Companies
Shilpa Pharma is not only a partner for large multinational corporations — we are equally committed to supporting early-stage European biotech and pharma startups. Many European biotech companies face the challenge of accessing world-class CDMO capabilities without the capital to engage large EU-based contract manufacturers. Our India-based CDMO model solves this by offering flexible batch sizes, milestone-based engagement structures, hands-on regulatory guidance, and a structured development-to-commercialization pathway — all within a single trusted partner relationship.
From pre-IND development and Phase I clinical supply through Phase II and III manufacturing and eventual commercial launch, European startups can scale confidently with Shilpa Pharma as their CDMO partner in India, without needing to switch organizations at any stage of growth.
Cost Advantage of Partnering with a CDMO in India for European Companies
One of the most significant strategic advantages of outsourcing to a CDMO in India is cost efficiency. Shilpa Pharma’s India-based manufacturing delivers 30 to 50 percent cost savings compared to equivalent EU-based CMO or in-house manufacturing options — without any compromise on quality, regulatory compliance, or supply reliability. For European pharmaceutical companies operating in a high-cost environment with increasing regulatory and ESG obligations, partnering with a CDMO in India like Shilpa Pharma provides a meaningful competitive advantage that can be reinvested into clinical programs, R&D pipelines, or market expansion.
Your Trusted CDMO Partner in India for the European Market
For European pharmaceutical and biotech companies seeking a dependable CDMO in India, Shilpa Pharma offers transparent operations, advanced technology platforms, EU GMP-certified manufacturing, and world-class scientific expertise designed to support your long-term growth and regulatory success across European markets.
Ready to collaborate with a trusted global CDMO in India for your European program?
Connect with Shilpa Pharma today to explore customized CMO and CDMO solutions tailored for the European pharmaceutical market.
